AU2008287367B2 - Triazole compounds that modulate HSP90 activity - Google Patents

Triazole compounds that modulate HSP90 activity Download PDF

Info

Publication number
AU2008287367B2
AU2008287367B2 AU2008287367A AU2008287367A AU2008287367B2 AU 2008287367 B2 AU2008287367 B2 AU 2008287367B2 AU 2008287367 A AU2008287367 A AU 2008287367A AU 2008287367 A AU2008287367 A AU 2008287367A AU 2008287367 B2 AU2008287367 B2 AU 2008287367B2
Authority
AU
Australia
Prior art keywords
optionally substituted
nrior
compound
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008287367A
Other languages
English (en)
Other versions
AU2008287367A1 (en
Inventor
Dinesh U. Chimmanamada
Keizo Koya
Hao Li
Teresa Przewloka
Lijun Sun
Weiwen Ying
Shijie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2008287367A1 publication Critical patent/AU2008287367A1/en
Application granted granted Critical
Publication of AU2008287367B2 publication Critical patent/AU2008287367B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008287367A 2007-08-13 2008-08-13 Triazole compounds that modulate HSP90 activity Ceased AU2008287367B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96444707P 2007-08-13 2007-08-13
US60/964,447 2007-08-13
PCT/US2008/009667 WO2009023211A1 (en) 2007-08-13 2008-08-13 Triazole compounds that modulate hsp90 activity

Publications (2)

Publication Number Publication Date
AU2008287367A1 AU2008287367A1 (en) 2009-02-19
AU2008287367B2 true AU2008287367B2 (en) 2012-02-23

Family

ID=39884398

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008287367A Ceased AU2008287367B2 (en) 2007-08-13 2008-08-13 Triazole compounds that modulate HSP90 activity

Country Status (14)

Country Link
US (3) US8742133B2 (OSRAM)
EP (1) EP2193135A1 (OSRAM)
JP (1) JP5596543B2 (OSRAM)
KR (1) KR20100057030A (OSRAM)
CN (1) CN101801983B (OSRAM)
AU (1) AU2008287367B2 (OSRAM)
BR (1) BRPI0815116A2 (OSRAM)
CA (1) CA2695995C (OSRAM)
IL (1) IL203663A (OSRAM)
MX (1) MX2010001565A (OSRAM)
NZ (1) NZ583205A (OSRAM)
TW (1) TWI438199B (OSRAM)
WO (1) WO2009023211A1 (OSRAM)
ZA (1) ZA201001064B (OSRAM)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072759B (zh) 2004-11-18 2013-06-19 Synta医药公司 调节hsp90活性的三唑化合物
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
US8053456B2 (en) 2006-05-25 2011-11-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP2026797A2 (en) 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Method for treating non-hodgkin's lymphoma
BRPI0807219A2 (pt) 2007-02-08 2015-05-26 Synta Pharmaceuticals Corp Composto de tiazol que modulam a atividade de hsp90
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
HRP20141150T1 (hr) * 2009-10-19 2015-01-30 Synta Pharmaceuticals Corp. Kombinacijska terapija raka sa hsp90 inhibitornim spojevima
US20130156755A1 (en) 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
JPWO2012026433A1 (ja) * 2010-08-23 2013-10-28 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
WO2012078757A2 (en) 2010-12-08 2012-06-14 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012116061A1 (en) 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
EP2678014A2 (en) 2011-02-24 2014-01-01 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
EP2714039A1 (en) * 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012162372A1 (en) 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2714033A1 (en) * 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
JP2014532712A (ja) * 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
JP2014534228A (ja) * 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
AU2013243381A1 (en) * 2012-04-04 2014-10-09 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate Hsp90 activity
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CN103664910B (zh) * 2012-09-14 2017-07-04 南京大学 含1，4‑苯并二噁烷的1，2，4‑三氮唑类衍生物及其制法与其抗菌活性
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
JP6497767B2 (ja) 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
BR112017016973A2 (pt) 2015-02-09 2018-04-03 Synta Pharmaceuticals Corp. terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer
JP6356364B1 (ja) 2015-05-20 2018-07-11 アムジエン・インコーポレーテツド Ａｐｊ受容体のトリアゾールアゴニスト
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2021119358A1 (en) * 2019-12-10 2021-06-17 Washington University Debaryomyces species as an indicator of non-healing ulcers in crohn's disease
CN113121505B (zh) * 2021-03-02 2023-03-07 中国人民解放军海军军医大学 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用
US20240226067A9 (en) * 2021-03-02 2024-07-11 The Johns Hopkins University Anti-fibrotic therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167070A1 (en) * 2004-11-18 2006-07-27 Weiwen Ying Triazole compounds that modulate Hsp90 activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621245B2 (en) * 1989-10-17 1992-03-05 Boehringer Mannheim Gmbh Hydrolase substrates, a process for the preparation thereof and agents containing them
WO2004111193A2 (en) * 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
US8399464B2 (en) * 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CN101160291B (zh) * 2005-03-09 2012-09-05 日本化药株式会社 作为hsp90抑制剂的三唑衍生物
US7781462B2 (en) * 2005-07-25 2010-08-24 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
US20070219129A1 (en) * 2005-08-17 2007-09-20 Pritchard Kirkwood A Jr hsp90 decoy peptides and uses thereof
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007021877A1 (en) * 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
US8183384B2 (en) * 2006-05-25 2012-05-22 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8318790B2 (en) * 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8053456B2 (en) * 2006-05-25 2011-11-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
TW200806637A (en) * 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167070A1 (en) * 2004-11-18 2006-07-27 Weiwen Ying Triazole compounds that modulate Hsp90 activity

Also Published As

Publication number Publication date
US8742133B2 (en) 2014-06-03
JP2010536753A (ja) 2010-12-02
AU2008287367A1 (en) 2009-02-19
WO2009023211A1 (en) 2009-02-19
TWI438199B (zh) 2014-05-21
US20140296186A1 (en) 2014-10-02
MX2010001565A (es) 2010-04-27
NZ583205A (en) 2012-03-30
US20150366885A1 (en) 2015-12-24
BRPI0815116A2 (pt) 2015-01-27
TW200911788A (en) 2009-03-16
ZA201001064B (en) 2010-10-27
US9120745B2 (en) 2015-09-01
CA2695995A1 (en) 2009-02-19
IL203663A (en) 2015-08-31
CA2695995C (en) 2015-09-29
CN101801983A (zh) 2010-08-11
EP2193135A1 (en) 2010-06-09
US20110195094A1 (en) 2011-08-11
JP5596543B2 (ja) 2014-09-24
CN101801983B (zh) 2014-01-29
KR20100057030A (ko) 2010-05-28

Similar Documents

Publication Publication Date Title
AU2008287367B2 (en) Triazole compounds that modulate HSP90 activity
EP2038262B1 (en) Triazole compounds that modulate hsp90 activity
EP2035396B1 (en) Triazole compounds that modulate hsp90 activity
CA2682665C (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
AU2007267847B2 (en) Triazole compounds that modulate Hsp90 activity
CA2677481C (en) Triazole compounds that modulate hsp90 activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired